Theravance Biopharma logo
Theravance Biopharma
TBPH | NASDAQ
Chart Builder DCF Calculator
$17.03
$0.00 (0.00%)
At close: Sep 23, 2026, 4:00 PM ET

Theravance Biopharma Company Profile

Company profile explained

Company Profile

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.

Key Executives

Name Position
Rick E. Winningham Chief Executive Officer & Director
Stuart Knight Senior Vice President of IT&I and Chief Information Officer
Aine Miller Senior Vice President of Development & Head of Ireland Office
Aziz Sawaf Senior VP of Operations Strategy & CFO
Brett A. Grimaud Senior Vice President, General Counsel & Secretary
Rhonda F. Farnum Chief Business Officer and Senior Vice President of Commercial & Medical Affairs
Stacy L. Pryce Senior Vice President & Chief Strategy Officer

Latest SEC Filings

Date Type Title
Sep 28, 2026 4 Filing
Sep 25, 2026 SC 13D/A [Amend] Filing
Sep 24, 2026 4 Filing
Sep 24, 2026 4 Filing
Sep 24, 2026 4 Filing
Sep 24, 2026 4 Filing
Sep 24, 2026 4 Filing
Sep 24, 2026 4 Filing
Sep 24, 2026 4 Filing
Sep 24, 2026 4 Filing
View All SEC Filings ➞
Theravance Biopharma
Theravance Biopharma logo
Country United States
IPO Date May 16, 2014
Industry Biotechnology
Sector Healthcare
Employees 90
CEO Rick E. Winningham

Contact Details

901 Gateway Boulevard South San Francisco, California 94080 United States

Stock Details

Ticker Symbol TBPH
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001583107
CUSIP Number G8807B106
ISIN Number KYG8807B1068
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.